Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions
The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This include...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacokinetics 2004, Vol.43 (1), p.1-15 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 15 |
---|---|
container_issue | 1 |
container_start_page | 1 |
container_title | Clinical pharmacokinetics |
container_volume | 43 |
creator | BAPTISTA, Trino NG YING KIN, N. M. K BEAULIEU, Serge |
description | The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population. |
doi_str_mv | 10.2165/00003088-200443010-00001 |
format | Article |
fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A199858512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A199858512</galeid><sourcerecordid>A199858512</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-3a5a61229702f8f4cc4b67de120ab6a2b722afea7324055d537eef49c7fc65263</originalsourceid><addsrcrecordid>eNptkU1L5TAUhsPgMF51_sIQEJd1cvLV1p2IHwPCbHRdTtNEM7bNJUkX99-b672jCCaLwJvnOYS8hFBg5xy0-s3KEqxpKs6YlIIBq7YRfCMrgLqtoOX6gKyYAF6pVotDcpTSv0I0RfhBDkHWoJhsVuTlIVrMk50zDY7mZ0snm7EPozd08CkvscfZ2EQNLskOtN9QnLNfp415DnkLxeUpXdCbYJZEw0zXIZdhHse3G-rnbCOa7MOcTsh3h2OyP_fnMXm8uX64uqvu_97-ubq8r4xQIlcCFWrgvK0Zd42Txshe14MFzrDXyPuac3QWa8ElU2pQorbWydbUzmjFtTgmp7u5Tzjazs8u5PKEySfTXULbNqpRwAt1_gVV9mAnb8JsnS_5J6HZCSaGlKJ13Tr6CeOmA9Zta-n-19K91_IWQVF_7dT10k92-BD3PRTgbA9gMji6WD7dpw9OSS1ASPEKKq-VMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>BAPTISTA, Trino ; NG YING KIN, N. M. K ; BEAULIEU, Serge</creator><creatorcontrib>BAPTISTA, Trino ; NG YING KIN, N. M. K ; BEAULIEU, Serge</creatorcontrib><description>The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-200443010-00001</identifier><identifier>PMID: 14715048</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Antipsychotic Agents - adverse effects ; Biological and medical sciences ; Drug Interactions ; Drug toxicity and drugs side effects treatment ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - pharmacokinetics ; Hypoglycemic Agents - therapeutic use ; Hypolipidemic Agents - adverse effects ; Hypolipidemic Agents - pharmacokinetics ; Hypolipidemic Agents - therapeutic use ; Medical sciences ; Metabolic Syndrome - chemically induced ; Metabolic Syndrome - drug therapy ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology</subject><ispartof>Clinical pharmacokinetics, 2004, Vol.43 (1), p.1-15</ispartof><rights>2004 INIST-CNRS</rights><rights>COPYRIGHT 2004 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c353t-3a5a61229702f8f4cc4b67de120ab6a2b722afea7324055d537eef49c7fc65263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15463134$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14715048$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BAPTISTA, Trino</creatorcontrib><creatorcontrib>NG YING KIN, N. M. K</creatorcontrib><creatorcontrib>BEAULIEU, Serge</creatorcontrib><title>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Drug Interactions</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Hypolipidemic Agents - adverse effects</subject><subject>Hypolipidemic Agents - pharmacokinetics</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Medical sciences</subject><subject>Metabolic Syndrome - chemically induced</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkU1L5TAUhsPgMF51_sIQEJd1cvLV1p2IHwPCbHRdTtNEM7bNJUkX99-b672jCCaLwJvnOYS8hFBg5xy0-s3KEqxpKs6YlIIBq7YRfCMrgLqtoOX6gKyYAF6pVotDcpTSv0I0RfhBDkHWoJhsVuTlIVrMk50zDY7mZ0snm7EPozd08CkvscfZ2EQNLskOtN9QnLNfp415DnkLxeUpXdCbYJZEw0zXIZdhHse3G-rnbCOa7MOcTsh3h2OyP_fnMXm8uX64uqvu_97-ubq8r4xQIlcCFWrgvK0Zd42Txshe14MFzrDXyPuac3QWa8ElU2pQorbWydbUzmjFtTgmp7u5Tzjazs8u5PKEySfTXULbNqpRwAt1_gVV9mAnb8JsnS_5J6HZCSaGlKJ13Tr6CeOmA9Zta-n-19K91_IWQVF_7dT10k92-BD3PRTgbA9gMji6WD7dpw9OSS1ASPEKKq-VMQ</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>BAPTISTA, Trino</creator><creator>NG YING KIN, N. M. K</creator><creator>BEAULIEU, Serge</creator><general>Adis international</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2004</creationdate><title>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</title><author>BAPTISTA, Trino ; NG YING KIN, N. M. K ; BEAULIEU, Serge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-3a5a61229702f8f4cc4b67de120ab6a2b722afea7324055d537eef49c7fc65263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Drug Interactions</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Hypolipidemic Agents - adverse effects</topic><topic>Hypolipidemic Agents - pharmacokinetics</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Medical sciences</topic><topic>Metabolic Syndrome - chemically induced</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BAPTISTA, Trino</creatorcontrib><creatorcontrib>NG YING KIN, N. M. K</creatorcontrib><creatorcontrib>BEAULIEU, Serge</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BAPTISTA, Trino</au><au>NG YING KIN, N. M. K</au><au>BEAULIEU, Serge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>2004</date><risdate>2004</risdate><volume>43</volume><issue>1</issue><spage>1</spage><epage>15</epage><pages>1-15</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>14715048</pmid><doi>10.2165/00003088-200443010-00001</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0312-5963 |
ispartof | Clinical pharmacokinetics, 2004, Vol.43 (1), p.1-15 |
issn | 0312-5963 1179-1926 |
language | eng |
recordid | cdi_gale_infotracmisc_A199858512 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Antipsychotic Agents - adverse effects Biological and medical sciences Drug Interactions Drug toxicity and drugs side effects treatment Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - pharmacokinetics Hypoglycemic Agents - therapeutic use Hypolipidemic Agents - adverse effects Hypolipidemic Agents - pharmacokinetics Hypolipidemic Agents - therapeutic use Medical sciences Metabolic Syndrome - chemically induced Metabolic Syndrome - drug therapy Miscellaneous (drug allergy, mutagens, teratogens...) Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology |
title | Treatment of the metabolic disturbances caused by antipsychotic drugs: Focus on potential drug interactions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T13%3A52%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20the%20metabolic%20disturbances%20caused%20by%20antipsychotic%20drugs:%20Focus%20on%20potential%20drug%20interactions&rft.jtitle=Clinical%20pharmacokinetics&rft.au=BAPTISTA,%20Trino&rft.date=2004&rft.volume=43&rft.issue=1&rft.spage=1&rft.epage=15&rft.pages=1-15&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-200443010-00001&rft_dat=%3Cgale_cross%3EA199858512%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14715048&rft_galeid=A199858512&rfr_iscdi=true |